A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy

Go Back to All Clinical Trials

A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy

Brief description of study

If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal of this study is to determine whether treatment with the study drug, sacituzumab govitecan, improves tumor shrinkage, and if so, how long tumor shrinkage lasts. This study will also evaluate how well the study drug works and how well tolerated it is.

Clinical Study Identifier: s18-00380

ClinicalTrials.gov Identifier: NCT03547973

Principal Investigator: Scot Niglio.

Other Investigators: Victor Ricardo Adorno Febles, Katie S. Murray, Wei Phin Tan, Laura Catherine Bauer, Hank Ng, David R. Wise.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies